sunitinib malate

Sunitinib malate
Sunitinib malate
Sunitinib malate.
Heart failure associated with sunitinib malate
Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
A phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC).
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previ...
Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma.
Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients...
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after i...
A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers ...